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Breast cancer has the highest incidence of any cancer in the
UK with over 45,000 new cases diagnosed each year.1
Axillary node status is recognised as the single most impor-
tant prognostic indicator of survival in these patients. Since
the advent of effective surgical management of breast can-
cer by Halsted at the end of the 19th century,2 and his use of
radical mastectomy with axillary lymph node dissection,
there has been a continual effort to optimise locoregional
surgery, both in terms of morbidity and mortality for breast
cancer patients. A key component to this effort has been the
development of an appropriate method of assessing the sta-
tus of the axillary lymph nodes following on from the intro-
duction of four-node sampling (ANS) over 30 years ago.3,4
The incorporation of sentinel lymph node biopsy (SLNB),
originally pioneered in penile cancer in the late 1970s5 and
then adapted for use with melanoma patients,6 into breast
cancer management began in 1993.7 This first report docu-
mented the identification of SLNB with radioisotopes; the
following year, SLNB localisation using blue dye alone was
reported by Giuliano et al.8 Finally, Albertini et al.9 intro-
duced the concept of combining radioactive isotope and
blue dye (‘dual localisation’) in 1996. A recent meta-analysis
of over 8000 patients concluded that dual localisation is the
method for optimising identification of the SLNB;10 indeed,
this is the method being introduced across the UK as part of
the NEW START training programme.
Surgeons today are faced with a variety of options when
considering how best to assess and manage the axilla
including: observation only; SLNB with dye only; SLNB with
isotope only; SLNB with dual localisation; blind ANS; blue-
dye-assisted ANS; and/or an axillary lymph node dissection
(ALND). Even within these options, there are further deci-
sions to be made, including the optimal site of injection of
radioisotope or dye, and which is the best dye or radioiso-
tope to use. Added to this, there are issues in relation to the
value of internal mammary node dissection, the role and
value of scintigraphy, and pre-operative axillary ultrasound
and percutaneous axillary node core biopsy and fine-needle
aspiration (FNA). Furthermore, once the status of the axilla
is established, there then arises the question of how to man-
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ABSTRACT
INTRODUCTION The aims of this study were to investigate the practice of axillary lymph node management within different
units throughout the UK, and to assess changes in practice since our previous survey in 2004.
SUBJECTS AND METHODS A structured questionnaire was sent to 350 members of the British Association of Surgical Oncology.
RESULTS There were 177 replies from respondents who managed more than 100 patients a year with breast cancer. Of these:
12 did not perform axillary ultrasound at all in their centre; 17 (10%) employed axillary node clearance (ANC) on all patients;
122(69%) performed sentinel node biopsy (SNB) with dual localisation; and 111 respondents had attended the New Start
Course. Radioisotope was most frequently injected 2 h or more before operation. Just 13 surgeons were convinced of the value
of dissecting internal mammary nodes visualised on a scan. Reasons for not using dual localisation included lack of nuclear
medicine facilities, no local ARSAC licence holder, no probe, and no funding. Sixty-six surgeons stated that, if they had an
ARSAC licence and could inject the radioactivity in theatre, this would be a major improvement. In addition, 83 (47%) did not
perform SLNB in patients receiving neo-adjuvant chemotherapy.
CONCLUSIONS Despite significant changes since 2004, substantial variation remains in management of the axilla. A number
of surgeons are practicing outwith current guidelines.
GLYNN WILLIAMS DIXON A FURTHER SURVEY OF SURGICAL MANAGEMENT OF THE AXILLA IN
UK BREAST CANCER PATIENTS
Ann R Coll Surg Engl 2010; 92: 506–511 507
age a patient with involved sentinel nodes and whether to
proceed to ALND, consider axillary radiotherapy or to per-
form no further axillary surgery in the presence of low vol-
ume axillary disease.
A previous survey by us in 2004 demonstrated a lack of
consensus across the UK in relation to the use of SLNB in
breast cancer patients.11 Further work, published recently
by Mansfield et al.,12 concluded that just 52% of surgeons
use SLNB in patients who have a clinically node-negative
breast cancer. The principal objective of this study was to
build on previous work, and to assess the conformity with
which surgeons in the UK are approaching issues related to
the axilla, including SLNB, internal mammary biopsy, axil-
lary ultrasound, and scintigraphy. A second aim of the study
was to establish satisfaction levels with the current NEW
START programme, and was to identify those factors which
are making it difficult for surgeons to incorporate the use of
sentinel node biopsy.
Subjects and Methods
A structured questionnaire was distributed to 350 Association
of Breast Surgery (ABS) associates, at the British Association of
Surgical Oncology (BASO), throughout the UK, in the summer
of 2008. The questionnaire was divided into three sections.
The first section collected information related to the post in
which the surgeon was working, including the type and size of
breast unit, the number of breast cancer patients treated per
year, and whether they performed other types of surgery. The
second series of questions focused on axillary investigation
and surgery, including the use of pre-operative axillary ultra-
sound scans, and the use of SLNB. Further details of proce-
dures were also sought. The final series of questions related to
the use of radioisotope and blue dye and attendence at the
NEW START programme.
Results
Demographic data
A total of 177 questionnaires (50.1%) were returned com-
pleted. Of these, 168 (95%) were consultants, with the
remainder being staff grades and registrars working in
breast units around the UK. Data on the surgeon’s back-
ground are presented in Table 1. Of respondents, 117
(66.1%) treated greater than 100 patients per year, whilst
just less than 2% treated less than 50. Overall, 174 (98%)
practiced in either a specialist breast unit or a breast unit
within a district general hospital and 152 (86%) worked in
hospitals with nuclear medicine facilities. Those surgeons
treating greater than 100 breast cancer patients per year
were less likely to perform other types of surgery (P =
0.041). That said, 60% of surgeons (107 of 177) had an on-
call commitment for general surgical emergencies.
Axillary ultrasound
A total of 114 (65%) surgeons organised or performed axil-
lary ultrasound on all patients with proven invasive cancer,
50 performed it on selected patients and 12 never used this
investigation. Actions taken as a result of an abnormal or
suspicious ultrasound scan are shown in Figure 1.
Axillary node clearance (ANC)
Of surgeons, 146 (82%) performed ANC regularly and
almost 10% (n = 17) performed it on all patients with breast
cancer. Of those respondents who maintained a selective
policy in relation to ANC (n = 154), 13 performed ANC for all
patients undergoing breast conserving surgery whereas 116
(75%) performed ANC only for patients with proven lymph
node involvement undergoing breast conserving surgery.
Thirty-four (22%) performed ANC for all patents with inva-
sive cancer undergoing mastectomy, with 96 (62%) per-
forming ANC only for patients with proven lymph node
involvement undergoing mastectomy.
Axillary node sampling
Fifty-four (30.5%) surgeons performed ANS on a regular
basis with the majority performing a blue-dye directed ANS.
Over 95% (102 of 107) of respondents used patent blue V
with the remainder using methylene blue. Of 111 surgeons
who answered the question, 17 (15%) injected dye at more
than one anatomical site. The most common sites for injec-
tion of dye were subareolar (n = 44) and peri-areolar (n =
44) Less common sites included peritumoural and intrader-
mal. Some surgeons did perform an axillary sampling pro-
cedure without blue dye, with the majority performing a
level 1 axillary dissection (n = 15).
Sentinel lymph node biopsy (SLNB)
Overall, 122 (69%) surgeons performed SLNB regularly
with dual localisation; one surgeon used SLNB with
radioisotope only. However, 133 (75%) performed SLNB
with radioisotope, at least occasionally. SLNB was employed
Figure 1 Actions taken following abnormal or suspicious axillary ultra-
sound. FNAC, fine needle aspiration cytology; USS, ultrasound scan.
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most commonly for patients who were clinically and ultra-
sound node negative, as demonstrated in Figure 2. When
the lesion was palpable, radioisotope was injected in the
nuclear medicine department in the vast majority (123 of
137; 90%) of cases. A similar situation applied for cases of
impalpable cancer (111 of 133; 83%); 13 surgeons injected
isotope in the X-ray department during localisation.
Radioisotope was rarely injected in the ward and operating
theatre. Of 136 surgeons who responded to the question, 80
(59%) injected the blue dye and radioisotope at the same
anatomical site. The most common sites for injection of
blue dye were subareolar (n = 67) and peri-areolar (n = 67).
The most popular sites for injection of radioisotope were
peri-areolar (n = 61), intradermal (n = 36), and subareolar
(n = 34). A significant number of respondents (22 of 136;
16%) chose to inject radioisotope at more than one anatom-
ical location. The vast majority (105 of 135; 78%) of sur-
geons using radioisotope injected it more than 2 h prior to
the operation. Factors most frequently identified as inhibit-
ing the use of SLNB with radioactivity included a lack of
nuclear medicine facilities, no local ARSAC licence holder,
and a lack of funding. Sixty-six surgeons stated that, if they
had an ARSAC licence and could inject the radioactivity in
theatre, this would be a major improvement. Forty-three
thought this would be of no improvement and 23 thought
this would not be acceptable because no scintigraphy would
be possible.
Sentinel lymph node biopsy and neo-adjuvant chemotherapy
Eighty-three surgeons did not perform SLNB in patients
receiving neo-adjuvant chemotherapy; 30 performed it
prior to chemotherapy, and a further 25 performed it post-
Question Option Result (%)
Which grade of surgeon applies to you? Consultant 95
SpR 3
Staff Grade/Ass Specialist 2
How many breast cancer patients do you treat in one year? <50 2
50-100 32
>100 66
Which of the following best applies to the setting in which you work? Specialist Breast Unit 39
Breast Unit with in DGH 59
General Surgical 2
What other types of surgery do you perform? General 61
Endocrine 27
GI 7
Other 17
Nil 20
Do you have an on-call commitment for general surgical emergencies? Yes 60
No 40
Does you hospital have nuclear medicine facilities? Yes 86
No 14
ASS, Associate; DGH, District General Hospital; GI, Gastro-Intestinal; SpR, Specialist Registrar
Table 1 Demographic Data
Figure 2 Indications for sentinel node biopsy. (A) Clinically node-
negative patients (n = 22); (B) clinically and ultrasound node-neg-
ative patients (n = 83); (C) all patients, irrespective of imaging or
node status (n = 13); (D) clinically node-negative and clinically and
ultrasound node-negative patients (n = 29); (E) no answer (n = 28);
and (F) other (n = 2).
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chemotherapy if the patient was clinically node-negative at
diagnosis.
NEW START Programme
A total of 111 (62%) respondents had attended a NEW
START course; these represented 83% of those surgeons
working with radioisotope.
Scintiscan
Of those who responded to the questions on scintiscan (n =
137), 104 (75%) surgeons regularly performed the investi-
gation. Of 122 respondents, just 21 (17%) routinely removed
internal mammary nodes if visualised on scintiscan, and
only 13 (9%) of respondents were convinced that there was
value in dissecting internal mammary nodes visualised on
scintiscan; 86 (63%) were not convinced and 38 (28%) were
unsure of the value of excising internal mammary nodes.
Discussion
In this study, one questionnaire was sent to each centre, and
hence only 350 members out of the total ABS at BASO mem-
bership were surveyed. The surgeons involved in this study
had previously been surveyed in a similar questionnaire
distributed by us in 2004.11 A limitation of this study is the
relatively low rate of survey completion (50%), though
examination of the literature reveals this to be in line with,
and indeed exceed, the completion rate of similar studies in
the breast cancer arena. Two-thirds of the surgeons com-
pleting this current survey managed over 100 patients with
breast cancer per year. Since 2004,11 there have been
changes with a reduction from 70% to 60% of breast sur-
geons having an on-call commitment. There has been an
overall reduction in the number of breast surgeons doing
general surgery from 81% to 60%. There have also been
falls in the number doing endocrine surgery from 34% to
27% and GI surgery from 24% to 7%. This is in keeping
with the continued trend to breast cancer being looked after
by specialist breast surgeons rather than general surgeons
who have a specialist breast interest.
One change since the last survey has been the introduc-
tion of axillary ultrasound. There is now clear evidence that
this is of value;17 however, 7% of units do not use this at all
and 28% only use it selectively. This is a cost-effective
method of assessing the axilla and the evidence is that it has
considerable benefits and no harms. Further studies are
needed to identify the barriers as to why it is not used rou-
tinely in patients with invasive breast cancer. The particu-
lar value of ultrasound is that it identifies up to half of
patients who have involved nodes18,19 and these women can
be spared an unnecessary sentinel node biopsy (SNB). In
those units who utilise axillary ultrasound, the majority
investigate suspicious nodes with FNA or core biopsy with
smaller numbers utilising a combination of the two. A
minority (10 surgeons) accept the ultrasound result and do
not perform FNAC or core biopsy. Ultrasound is neither suf-
ficiently sensitive nor specific to be used alone; in patients
with indeterminate cortical thickening in the range of 2–4
mm, it is essential to assess whether such patients have
involved nodes by FNAC or core biopsy.20–23
The majority of surgeons continue to perform ANC
which is an appropriate treatment for involved axillary
nodes. Axillary radiotherapy is another option for involved
nodes, and this is used in some centres and has been shown
to produce good long-term disease control rate.24 A ran-
domised study of ANC versus axillary radiotherapy is on-
going. Approximately 10% of surgeons continue to perform
ANC on all patients with invasive breast cancer; this
includes 8.4% of surgeons who perform it routinely in
patients undergoing breast conserving surgery and 22%
who perform ANC on all patients with invasive cancer
undergoing mastectomy. The majority restrict ANC to
patients with involved axilla on cytology or follow a SNB.
ANC has significant morbidity25 and it is difficult to support
the routine use of ANC in patients without definite proof of
axillary node involvement.
Almost a third of surgeons perform axillary node sample
(ANS) on a regular basis. The majority perform blue dye
directed sampling. There has been a considerable change
where in the breast the blue dye is injected. Previously, 82%
of surgeons injected blue dye around the tumour,11 whereas
now 80% inject it in the subareolar or peri-areolar regions.
There remain some surgeons who perform a level I axillary
dissection rather than an ANS or SNB. With the considerable
literature demonstrating the efficacy of SNB,26–28 the on-going
use of lower axillary dissection as a method of assessing node
status of the axilla is difficult to support. Studies with reverse
axillary mapping where blue dye is injected into the upper
arm have shown that there are lymphatics in the lower axilla
which drain the arm and these will be potentially damaged by
a level I dissection where they aremuchmore likely to be pre-
served by a SNB.29
Increasing numbers of surgeons are performing SNB regu-
larly. Only 36% in our previous survey were performing SNB
outside of trials whereas 69% of surgeons now perform dual
localisation SNB. SNB is appropriately employed by most sur-
geons in patients who are clinically and ultrasound node-neg-
ative. Radioisotope is, in the majority, injected in the nuclear
medicine department although radioisotope is sometimes
injected in the ward and in the operating theatre. The majori-
ty of surgeons inject blue dye and radioisotope in the same
anatomical location with the most common site for injection
being subareolar or peri-areolar.
The injection of blue dye and radioactivity at the same
site is in keeping with the literature which suggests that
drainage to the axilla is the same regardless of the site of
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injection.30–32 Nonetheless, 40% of surgeons inject blue dye
and radioactivity at different sites. Radioisotope is most
frequently injected more than 2 h prior to surgery,
although recent data have shown that localisation rates
are identical regardless of the time the radioisotope is
injected.29,34 This includes injecting the radioisotope in the
anaesthetic room after induction of anaesthesia. Factors
identified as inhibiting the use of SNB include a lack of
nuclear medicine facilities in the hospital, no local ARSAC
licence holder and a lack of funding. When asked what
would be the one change in practice which would have the
benefit, almost one half of surgeons stated that the acqui-
sition of an ARSAC licence and the ability to inject the
radioactivity when the patient has been anaesthetised
would be a major improvement. A third thought this would
not be of any advantage and one in six thought this would
not be a disadvantage because scintigraphy could not be
performed prior to surgery.
The results of this analysis have demonstrated the lack
of consensus regarding the use of SNB in the setting of neo-
adjuvant chemotherapy. There have been numerous dis-
cussions about the value of performing SNB both prior to,
and following, neo-adjuvant treatment,36–39 but it appears
there remains a divergence of views amongst surgeons as to
the most appropriate practice in this context.
There continues to be uncertainty about the value of
scintigraphy and the value of removing internal mammary
nodes. Only 17% of surgeons remove internal mammary
nodes routinely if visualised on the scan and only 9% of sur-
geons are convinced that there is value in dissecting out
internal mammary nodes. Almost two-thirds are not con-
vinced of the value of removing internal mammary nodes.
The number of patients with isolated internal mammary
nodes is small.40 Although the morbidity associated with
removal of the internal mammary nodes has been reported
by some to be small,40 the procedure can involve a second
skin incision and mobilisation of large amount of tissue.
There also remains controversy as to whether once internal
mammary node metastases are identified it is possible to
give adequate doses of radiotherapy to these areas without
including significant amounts of underlying heart in the
radiation fields,41 particularly on the left side.
Conclusions
There have been significant changes in the management of
the axilla since the previous survey. SNB is now much more
widely used but there remain units where SNB cannot be
performed. Barriers have been identified and these need to
be overcome if equal access to the same standard of care is
available throughout the UK. Wide variations in practice
have been identified which are not evidence based.
Consensus and standards of care need to be defined to
ensure treatment is based on stage of disease rather than
which surgeon manages a patient.
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